Fujian Haixi Pharmaceuticals Co (HKSE:02637) OCF Margin %: 27.45% (As of Dec. 2025) — 27% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02637 Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
23 GF Score
Price HK$204.80
! 2 Warning Signs
View Full Analysis

What is Fujian Haixi Pharmaceuticals Co OCF Margin %?

Fujian Haixi Pharmaceuticals Co HKSE:02637 +3.28% 23 OCF Margin % is 27.45% as of Dec. 2025, which is 27% below its 10-year median of 37.64. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 90.63% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Fujian Haixi Pharmaceuticals Co's Cash Flow from Operations for the six months ended in Dec. 2025 was HK$176.6 Mil. Fujian Haixi Pharmaceuticals Co's Revenue for the six months ended in Dec. 2025 was HK$643.3 Mil. Therefore, Fujian Haixi Pharmaceuticals Co's OCF Margin % for the quarter that ended in Dec. 2025 was 27.45%.

As of today, Fujian Haixi Pharmaceuticals Co's current OCF Yield % is 1.10%.

The historical rank and industry rank for Fujian Haixi Pharmaceuticals Co's OCF Margin % or its related term are showing as below:

HKSE:02637' s OCF Margin % Range Over the Past 10 Years
Min: 27.45   Med: 37.64   Max: 46.46
Current: 27.45


During the past 4 years, the highest OCF Margin % of Fujian Haixi Pharmaceuticals Co was 46.46%. The lowest was 27.45%. And the median was 37.64%.

HKSE:02637's OCF Margin % is ranked better than
90.63% of 961 companies
in the Drug Manufacturers industry
Industry Median: 9.77 vs HKSE:02637: 27.45


Fujian Haixi Pharmaceuticals Co OCF Margin % Related Terms


Fujian Haixi Pharmaceuticals Co OCF Margin % Historical Data

* Premium members only.

The historical data trend for Fujian Haixi Pharmaceuticals Co's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fujian Haixi Pharmaceuticals Co OCF Margin % Chart

Fujian Haixi Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
OCF Margin %
40.15 46.46 35.13 27.45

Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
OCF Margin % 40.15 46.46 35.13 27.45

HKSE:02637 vs ZTS: OCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fujian Haixi Pharmaceuticals Co OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's OCF Margin % falls into.


HKSE:02637
23GF Score
Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fujian Haixi Pharmaceuticals Co OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Fujian Haixi Pharmaceuticals Co's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=176.626/643.346
=27.45 %

Fujian Haixi Pharmaceuticals Co's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=176.626/643.346
=27.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 27.45% mean?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a OCF Margin % of 27.45% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is 27% below median its historical median of 37.64. Over the past decade, Fujian Haixi Pharmaceuticals Co's OCF Margin % has ranged from 27.45 to 46.46. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #90 out of 961 companies in the Drug Manufacturers industry, placing it in the top 9.4%.
Is Fujian Haixi Pharmaceuticals Co's OCF Margin % too high?
Fujian Haixi Pharmaceuticals Co's current OCF Margin % of 27.45% is 27% below median its 10-year median of 37.64. Over the past 10 years, this metric has ranged from a low of 27.45 to a high of 46.46. The Drug Manufacturers industry median OCF Margin % is 9.77. Fujian Haixi Pharmaceuticals Co's value of 27.45% is 181% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #90 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #90 out of 961 companies for OCF Margin %. This places Fujian Haixi Pharmaceuticals Co in the top 9% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.77. Fujian Haixi Pharmaceuticals Co's value of 27.45% is 181% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own OCF Margin % has ranged from 27.45 to 46.46 over the past decade. While the company's 10-year median is 37.64 vs. the industry median of 9.77, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.77, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current OCF Margin % of 27.45% is 181% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current OCF Margin % is 27.45%, which is 27% below median its own 10-year median of 37.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current OCF Margin % of 27.45%. The current OCF Margin % is 27.45%, which is 27% below median its 10-year median of 37.64 and 181% above the Drug Manufacturers industry median of 9.77. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current OCF Margin % is 27.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fujian Haixi Pharmaceuticals Co Business Description

Address No. 177 Jinda Road, Floor 3rd & 4th, Block B, Jianxin Town, Cangshan District,Fujian Province, Fuzhou, CHN, 350028
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score

Get the complete analysis for HKSE:02637

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$204.80
Price